Renal Allograft Fibrosis Study
Despite the reduction in acute rejection episodes in renal transplant patients due to modern
immunosuppression, proportionate improvements in long-term allograft survival have not been
achieved. Virtually any disease or injury affecting renal allografts can culminat...
Age: 18 years - 66+
Gender: All
Study of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA)
with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand
whether they cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) res...
Age: 18 - 80 years
Gender: All
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination
with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line
metastatic pancreatic ductal adenocarcinoma (mPDAC).
This study aims to explore ...
Age: 18 years - 66+
Gender: All
Pragmatic Implementation Trial of a CF Primary Palliative Care Intervention
Five Cystic Fibrosis (CF) centers, key stakeholders, and a palliative care institute have collaborated to create a novel primary palliative care intervention for patients with CF, "Improving Life with CF: A Primary Palliative Care Partnership," and established the infra...
Age: 12 years - 66+
Gender: All
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
This study will compare the effects of AXA1125, an orally active mixture of amino acids,
compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis
in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tol...
Age: 18 years - 66+
Gender: All
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3
Age: 18 years - 66+
Gender: All
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer
Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the
effect of Nintedanib on slowing the rate of lung disease in patients who have been d...
Age: 18 years - 66+
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver
transplantation as an option, even if controversial. In sicker recipients, LT results in
immediate survival, but poor medium-term survival rates in some studies. The scarcit...
Age: 18 - 80 years
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of...
Age: 18 - 80 years
Gender: All
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
Scarring of the lung, termed pulmonary fibrosis (PF), is a chronic, progressive, and usually
fatal disorder. While two anti-fibrotic drugs have been approved for treating PF of unknown
cause (idiopathic pulmonary fibrosis or IPF), neither drug is curative, and nearl...
Age: 40 years - 66+
Gender: All
A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
This study will evaulate the long-term safety, efficacy and pharmacokinetics (PK) of
recombinant human pentraxin-2 (rhPTX-2; PRM-151) administered by intravenous (IV) infusion to
participants with idiopathic pulmonary fibrosis (IPF).
Age: Birth - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression
of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an
accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing l...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747)
can lead to histological improvement in fibrosis with no worsening of NASH in adults with
compensated cirrhosis due to NASH.
Age: 18 years - 66+
Gender: All
Standardized Treatment of Pulmonary Exacerbations II
Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during
which symptoms of lung infection increase and lung function decreases. These pulmonary
exacerbations are treated with varying antibiotics for varying time periods based on need...
Age: 18 years - 66+
Gender: All